6-Thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease

Clinical Gastroenterology and Hepatology

Volumn 3, Issue 10, 2005, Pages 1007-1014

  Neurath, Markus F ^a   Kiesslich, Ralf ^a   Teichgräber, Ute ^a   Fischer, Christine ^b   Hofmann, Ute ^b   Eichelbaum, Michel ^b   Galle, Peter R ^a   Schwab, Matthias ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

6 THIOGUANOSINE DIPHOSPHATE; AZATHIOPRINE; DRUG METABOLITE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; NUCLEOTIDE; THIOGUANOSINE TRIPHOSPHATE; TIOGUANINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFECT; DRUG ERYTHROCYTE LEVEL; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; FEMALE; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; BIOLOGICAL MARKERS; CROHN DISEASE; ERYTHROCYTES; GUANINE NUCLEOTIDES; GUANOSINE DIPHOSPHATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; THIONUCLEOTIDES;

EID: 26244436603     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-3565(05)00697-X     Document Type: Article

References (38)

1. D.H. Present, B.I. Korelitz, N. Wisch Treatment of Crohn's disease with 6-mercaptopurine a long-term randomized, double-blind study N Engl J Med 302 1980 981 987
2. W. Huglus Double-masked trial of azathioprine in multiple sclerosis Lancet 2 1988 179 186
3. J.S. Maltzman, G.A. Koretzky Azathioprine old drug, new actions J Clin Invest 111 2003 1122 1124
4. K. Ewe, A. Press, C.C. Singe Azathioprine combined with prednisolone or monotherapy with prednisone in active Crohn's disease Gastroenterology 105 1993 367 376
5. M.F. Neurath, R. Wanitschke, M. Peters Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease Gut 44 1999 625 628
6. A.G. Fraser, T.R. Orchard, D.P. Jewell The efficacy of azathioprine for the treatment of inflammatory bowel disease a 30 year review Gut 50 2002 485 489
7. M.F. Neurath, S. Finotto, W. Strober Immunology of inflammatory bowel disease R.R. Rich 2nd ed. Clinical immunology 87 2001 St. Louis Mosby 1-87.21
8. T. Dervieux, T.L. Brenner, Y.Y. Hon De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo Blood 100 2002 1240 1247
9. S.B. Hanauer, B.I. Korelitz, P. Rutgeerts Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo a 2-year trial Gastroenterology 127 2004 723 729
10. S. Ardizzone, G. Maconi, G.M. Sampietro Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease Gastroenterology 127 2004 730 740
11. S. Candy, J. Wright, M. Gerber A controlled double blind study of azathioprine in the management of Crohn's disease Gut 37 1995 674 678
12. G.A. LePage Basic biochemical effects and mechanism of action of 6-thioguanine Cancer Res 23 1963 1202 1206
13. T. Dervieux, J.G. Blanco, E.Y. Krynetski Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells Cancer Res 61 2001 5810 5816
14. N.F. Krynetskaia, E.Y. Krynetski, W.E. Evans Human RNase H-mediated RNA cleavage from DNA-RNA duplexes is inhibited by 6deoxythioguanosine incorporation into DNA Mol Pharmacol 56 1999 841 848
15. L. Somerville, E.Y. Krynetski, N.F. Krynetskaia Structure and dynamics of thioguanine-modified duplex DNA J Biol Chem 278 2003 1005 1011
16. G.B. Elion The George Hitchings and Gertrude Elion Lecture. The pharmacology of azathioprine Ann N Y Acad Sci 685 1993 400 407
17. L. Quemeneur, L.M. Gerland, M. Flacher Differential control of cell cycle, proliferation, and survival of primary T lymphocytes by purine and pyrimidine nucleotides J Immunol 170 2003 4986 4995
18. C. Cuffari, E.G. Seidman, S. Latour Quantification of 6-thioguanine in peripheral blood leukocyte DNA in Crohn's disease patients on maintenance 6-mercaptopurine therapy Can J Physiol Pharmacol 74 1996 580 585
19. I. Tiede, G. Fritz, S. Strand CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes J Clin Invest 111 2003 1133 1145
20. M.C. Dubinsky, H. Yang, P.V. Hassard 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease Gastroenterology 122 2002 904 915
21. M.C. Dubinsky Azathioprine, 6-mercaptopurine in inflammatory bowel disease pharmacology, efficacy, and safety Clin Gastroenterol Hepatol 2 2004 731 743
22. S. Wright, D.S. Sanders, A.J. Lobo Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease Gut 53 2004 1123 1128
23. P.W. Lowry, C.L. Franklin, A.L. Weaver Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease Gut 49 2001 665 670
24. L.O. Reuther, J. Sonne, N.E. Larsen Pharmacological monitoring of azathioprine therapy Scand J Gastroenterol 38 2003 972 977
25. B. Wusk, G.A. Kullak-Ublick, C. Rammert Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis Eur J Gastroenterol Hepatol 16 2004 1407 1413
26. T. Kroplin, N. Weyer, S. Gutsche Thiopurine S-methyltransferase activity in human erythrocytes a new HPLC method using 6-thioguanine as substrate Eur J Clin Pharmacol 54 1998 265 271
27. E. Schaeffeler, T. Lang, U.M. Zanger High-throughput genotyping of thiopurine S-methyltransferase by denaturing HPLC Clin Chem 47 2001 548 555
28. E. Schaeffeler, C. Fischer, D. Brockmeier Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants Pharmacogenetics 14 2004 407 417
29. K.R. Herrlinger, K. Fellermann, C. Fischer Thioguanine-nucleotides do not predict efficacy of 6-tioguanine in Crohn's Disease Aliment Pharmacol Ther 19 2004 1269 1276
30. S.R. Rabel, J.F. Stobaugh, R. Trueworthy Determination of intracellular levels of 6-mercaptopurine metabolites in erythrocytes utilizing capillary electrophoresis with laser-induced fluorescence detection Anal Biochem 224 1995 315 322
31. G.R. Lichtenstein Use of laboratory testing to guide 6-mercaptopurine/ azathioprine therapy Gastroenterology 127 2004 1558 1564
32. M.C. Dubinsky, S. Lamothe, H.Y. Yang Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease Gastroenterology 118 2000 705 713
33. C. Cuffari, D.Y. Li, J. Mahoney Peripheral blood mononuclear cell DNA 6-thioguanine metabolite levels correlate with decreased interferon-gamma production in patients with Crohn's disease on AZA therapy Dig Dis Sci 49 2004 133 137
34. P. Gupta, R. Gokhale, B.S. Kirschner 6-mercaptopurine metabolite levels in children with inflammatory bowel disease J Pediatr Gastroenterol Nutr 33 2001 450 454
35. D.C. Pearson, G.R. May, G.H. Fick Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis Ann Intern Med 123 1995 132 142
36. M.F. Neurath, E. Stange Evidenzbasierte Immunsuppression bei chronisch entzündlichen Darmerkrankungen Deutsches Arzteblatt 97 2000 1977 1983
37. A. Mizrahi, S. Molshanski-Mor, C. Weinbaum Activation of the phagocyte NADPH oxidase by Rac guanine nucleotide exchange factors in conjunction with ATP and nucleoside diphosphate kinase J Biol Chem 280 2005 3802 3811
38. L. Lennard The clinical pharmacology of 6-mercaptopurine Eur J Clin Pharmacol 43 1992 329 335